Roy S Herbst, MD, Ph.D. of Yale Cancer Center explains the ESMO abstract – Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC.
New Haven, Conn.-According to revised findings led by Yale Cancer Center researchers, the treatment of osimertinib with targeted therapy following surgery appears to be important. In patients with early-stage, non-small cell lung cancer ( NSCLC) with epidermal growth factor receptor (EGFR) gene mutations, disease-free survival (DFS) is increased.
The advantage of treatment with osimertinib shown in the ADAURA trial earlier this year was such that the independent data monitoring committee recommended the early unblinding of the data Multinational Phase III randomized controlled trial. The new results are to be presented. September 19 at 12:30 p.m., during the Annual Meeting of the Virtual Science Program Society for Medical Oncology (ESMO) of Europe. The findings are also to be reported online in the Journal of Medicine of New England at the same time.
ADAURA is a randomized, phase 3 study that looked at adjuvant treatment with osimertinib, a medication called osimertinib. EGFR-TKI in the third generation versus placebo in the care of patients with Stage IB through IIIA Non-small cell lung cancer with EGFR-mutated. The findings of the trial have shown that osimertinib has given. For patients with resected lung cancer (stage IB / II / IIIA), 89 percent of DFS for two years compared to DFS for patients with resected lung cancer (stage IB / II / IIIA) 52 percent pace, with manageable side effects, in patients randomized to placebo therapy.
Disease-free survival tracks the time from randomization to cancer recurrence or the first symptom of cancer.
In this study, osimertinib-treated patients had a 79 percent reduction in their risk of returning or dying from cancer. For overall survival outcomes, the study will continue to follow patients.